NCC Limited Robust Financial Performance and Strategic Board Appointments for FY2025-26

NCC Limited announced strong financial results for the quarter and year ended March 31, 2026. The company reported a consolidated annual turnover of ₹20,944.40 crore and recommended a dividend of ₹2.20 per share. Alongside these financial achievements, NCC announced significant leadership changes, including the reappointment of Sri A V N Raju as Whole-time Director, the appointment of Smt. Kauslya Bhupathi Raju as Director (Commercial), and the election of Sri Rajender Mohan Malla as Chairman of the Board.

Annual Financial Highlights

NCC Limited delivered a solid performance for the financial year 2025-26. On a consolidated basis, the company reported an annual turnover of ₹20,944.40 crore. The company achieved a consolidated Net Profit attributable to shareholders of ₹675.32 crore. Recognizing this performance, the Board of Directors has recommended an equity dividend of 110%, amounting to ₹2.20 per share (face value of ₹2/-), subject to shareholder approval at the upcoming 36th Annual General Meeting, scheduled for August 27, 2026.

On the standalone front, the company posted an annual turnover of ₹17,669.28 crore and a Net Profit of ₹576.76 crore. As of March 31, 2026, the company holds a strong order book valued at ₹83,004 crore on a consolidated basis and ₹72,259 crore on a standalone basis.

Strategic Leadership Transitions

The company announced key organizational changes to strengthen its leadership team. Sri A V N Raju has been reappointed as Whole-time Director for a five-year term ending May 29, 2031. Furthermore, the company expanded its leadership by appointing Smt. Kauslya Bhupathi Raju as Director (Commercial), effective September 1, 2026. Additionally, Sri A Karthik has been appointed as the new Company Secretary and Compliance Officer, effective May 15, 2026.

Board Reconstitution

Following the completion of the term of Dr. A S Durga Prasad on May 23, 2026, the Board has elected Sri Rajender Mohan Malla as the new Chairman of the Board, effective May 24, 2026. In alignment with these changes, the company has successfully reconstituted its various Board Committees to ensure continued effective governance and oversight.

Source: BSE

Previous Article

Gland Pharma Limited Reports Strong Revenue and Profit Growth for FY26